tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM
PremiumThe FlyKyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM
1M ago
Premium
Ratings
Kyverna Therapeutics, Inc.: Strategic Developments and Promising Clinical Trials Drive Buy Rating
2M ago
Premium
Ratings
Kyverna Therapeutics’ KYV-101 Program Shows Promising Developments and Advances in Clinical Trials
2M ago
Kyverna Therapeutics initiated with an Outperform at William Blair
PremiumThe FlyKyverna Therapeutics initiated with an Outperform at William Blair
2M ago
Premium
Ratings
Kyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101
2M ago
Premium
Ratings
Kyverna Therapeutics: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
2M ago
PremiumCompany AnnouncementsKyverna Therapeutics Appoints New Chief Financial Officer
4M ago
Kyverna Therapeutics names Marc Grasso, M.D., as CFO
Premium
The Fly
Kyverna Therapeutics names Marc Grasso, M.D., as CFO
4M ago
Premium
Company Announcements
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100